SciELO - Scientific Electronic Library Online

 
vol.37 número4Retirada intermedia de esteroides después del trasplante renal y desarrollo de anticuerpos anti-HLA (Ac-antiHLA) índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google

Compartir


Nefrología (Madrid)

versión On-line ISSN 1989-2284versión impresa ISSN 0211-6995

Resumen

GIL-PENA, Helena  y  THE RENALTUBE GROUP et al. A new SLC12A3 founder mutation (p.Val647Met) in Gitelman's syndrome patients of Roma ancestry. Nefrología (Madr.) [online]. 2017, vol.37, n.4, pp.423-428. ISSN 1989-2284.  https://dx.doi.org/10.1016/j.nefro.2017.01.007.

Background:

Gitelman's syndrome (GS) is an autosomal recessive disorder caused by mutations in the SLC12A3 gene. GS is characterized by hypokalaemic metabolic alkalosis, hypomagnesemia and hypocalciuria. Most of the reported patients of Roma ancestry are homozygous for an SLC12A3 intron 9 frameshifting mutation (c.1180+1G>T). Some forms of Bartter's syndrome result from mutations in the CLNCKB gene and clinically overlap with GS.

Objectives:

To characterize a second SLC12A3 mutation in Roma patients negative for the intron 9 variant.

Methods:

SLC12A3 and CLNCKB genes were analyzed by next-generation sequencing in two Spanish and Greek gypsy patients who were negative for the intron 9 splicing mutation. Sanger sequencing was performed to confirm the putative mutations in patients and family members.

Results:

We identified a missense variant (p.Val647Met, c.1939G>A) in both cases, and both were homozygous for Met. This mutation was also found in three additional patients; two homozygous and one heterozygous compound with the intron 9 splicing mutation. This new SLC12A3 mutation seems to be characteristic of gipsy GS patients and was linked to the same haplotype in all cases, supporting a founder origin. All the patients showed biochemical features characteristic of GS.

Conclusion:

We report a second founder mutation among GS patients of Roma ethnic background. The direct screening of this mutation would facilitate the characterization of patients who are negative for the more common intron 9 +1G>T mutation.

Palabras clave : Gitelman’s síndrome; SLC12A3 gene; Gypsy patients; Roma genetic background.

        · resumen en Español     · texto en Inglés     · Inglés ( pdf )